Antagonists of
growth hormone-releasing hormone (GH-RH) inhibit growth of various human
cancers including
osteosarcomas and Ewing's
sarcomas, xenografted into nude mice or cultured in vitro. The antiproliferative effect of GH-RH antagonists could be mediated, in part, through the splice variants (SVs) of receptors for GH-RH which have been found in several human
cancers and
cancer cell lines. In this study we investigated the expression of SVs of GH-RH receptors and the binding characteristics of these receptor
isoforms in
MNNG/HOS human
osteosarcoma and SK-ES-1 human
Ewing's sarcoma grown in nude mice. RT-PCR revealed the presence of
mRNA for SVs of GH-RH receptors in both human malignant
bone cancer models. Using
ligand competition assays with 125I-labeled GH-RH antagonist JV-1-42, we demonstrated in
MNNG/HOS and SK-ES-1
tumors the presence of specific high affinity binding sites for GH-RH (Kd=5.83 nM and Kd=2.76 nM) with a maximal binding capacity (Bmax) of 552.1 fmol/mg
protein and 371.9 fmol/mg
protein, respectively. We also investigated the effect of GH-RH antagonist
JV-1-38, administered s.c. at a dose of 20 microg twice daily for 4 weeks on the gene expression, affinity and concentration of receptors for GH-RH in
MNNG/HOS human
osteosarcomas xenografted into nude mice. Treatment with
JV-1-38 did not affect the expression and binding characteristics of GH-RH receptors. High affinity binding of
JV-1-38 to GH-RH receptors on
MNNG/HOS
tumors was characterized by an IC50 value of 1.04 nM. The presence of GH-RH receptors in human bone
tumors provides a rationale for new approaches to the
therapy of this
malignancy based on GH-RH antagonists.